《Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer》.pdfVIP

Chinese Journal of Cancer Original Article - Re challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer 1,2 3,4 3 3 3 Khurum Khan , Gerard G Hanna , Lynn Campbell , Paula Scullin , Adnan Hussain , Ruth L Eakin3 and Jonathan McAleese3 Abstract Despite recent improvements to current therapies and the emergence of novel agents to manage ′ - advanced non-small cell lung cancer (NSCLC), the patients overall survival remains poor. Re challenging - with first line chemotherapy upon relapse is common in the management of small cell lung cancer but is not well reported for advanced NSCLC. NSCLC relapse has been attributed to acquired drug resistance, but - the repopulation of sensitive clones may also play a role, in which case re challenge may be appropriate. - Here, we report the results of re challenge with gemcitabine plus carboplatin in 22 patients from a single - institution who had previously received gemcitabine plus platinum in the first line setting and had either - partial response or a progression free interval of longer than 6 mont